Additional developments include:
-- Appointed Daniel S. Janney, a managing director of Alta Partners, a
venture capital firm investing in life sciences and information
technology companies, to the Anesiva board of directors.
- Completed successful public offering of common stock in December,
raising net proceeds of approximately $47.7 million.
Fourth Quarter and Fiscal Year 2007 Financial Results
Total operating expenses in the fourth quarter of 2007 were $18.1 million, including $1.7 million of non-cash stock-based compensation, compared to total operating expenses of $16.2 million, including $2.3 million of non-cash stock-based compensation, in the fourth quarter of 2006. For the year ended December 31, 2007, operating expenses were $61.5 million compared to $58.8 million for the year ended December 31, 2006.
Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch the company's lead product candidate, Zingo, a fast-acting, needle-free, local anesthetic. Additional operating expenses related to the ongoing development of Adlea, which has been shown in numerous clinical studies to provide site-specific, moderate-to-severe pain relief for weeks to months following a single application.
For the fourth quarter of 2007, Anesiva's net loss was $17.7 million,
or $0.60 per share. In the fourth quarter of 2006, the net loss was $15.3
million, or $0.65 per share. The ne
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved